Cláudia Bertan - Concepedia

Author

Cláudia Bertan

Also Known As

C Bertan, C Membrive, C. Bertan, C. M. B. MEMBRIVE, C. M. B. Membrive, C. M. Bertam Membrive, C.M. Membrive, C.M.B. Membrive, Claudia Maria Bertan Membrive, Claudia Bertan

249

Publications

Citations

H-Index

Concepts

All Affiliations

Institute of Cancer Research Royal Marsden NHS Foundation Trust Royal Marsden Hospital Vall d'Hebron Institute of Oncology Fondazione IRCCS Istituto Nazionale dei Tumori

About

Cláudia Bertan is an author at Institute of Cancer Research specializing in medicine, oncology, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	660
2	Public Health	5	5	142
3	Cell Biology	2	2	48
4	Health Sciences	1	1	39
5	Biology	1	1	30

Cláudia Bertan

Publications

4.2K

Citations

H-Index

Page 1

	Year	Citations
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial Joaquı́n Mateo, Núria Porta, Diletta Bianchini, The Lancet Oncology	2019	632
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer Alec Paschalis, Beshara Sheehan, Ruth Riisnaes, European Urology	2019	452
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition Jane Goodall, Joaquı́n Mateo, Wei Yuan, Cancer Discovery	2017	410
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer Adam Sharp, Ilsa M. Coleman, Wei Yuan, Journal of Clinical Investigation	2018	377
Genomics of lethal prostate cancer at diagnosis and castration resistance Joaquı́n Mateo, George Seed, Cláudia Bertan, Journal of Clinical Investigation UrologyOncologyGenomic AberrationsTumor HeterogeneityDdr Gene Defects	2019	292
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer Daniel Nava Rodrigues, Pasquale Rescigno, David Liu, Journal of Clinical Investigation	2018	203
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial Suzanne Carreira, Núria Porta, Sara Arce‐Gallego, Cancer Discovery	2021	157
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity Gunther Boysen, Daniel Nava Rodrigues, Pasquale Rescigno, Clinical Cancer Research	2018	138
Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer Susanna Zanutto, Sara Pizzamiglio, Marco Ghilotti, British Journal of Cancer	2014	130
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study Joaquı́n Mateo, Heather H. Cheng, Himisha Beltran, European Urology	2018	119

Page 1